alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › therapeutic-development

therapeutic-development

1 study tagged therapeutic-development, dated 2021-08-02. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Aducanumab: a new phase in therapeutic development for Alzheimer's disease? 2021-08-02

Studies

1 studies carry this tag.

Date range

2021

Top journals

  • EMBO molecular medicine 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Aducanumab: a new phase in therapeutic development for Alzheimer's disease?

    ✓ Peer-reviewed alzhub usefulness score 43 out of 100. EMBO molecular medicine 2021-08-02 Treatments

    On 7 June , the FDA approved aducanumab, the first new drug for Alzheimer's disease in almost 20 years-and notably, the first drug with a putative disease-modifying mechanism for the treatment of this devastating disorder, namely the removal of β-amyloid (or Aβ) plaques from the brain.

All topic tags with their study counts